Plus Therapeutics (NASDAQ:PSTV) Upgraded by Zacks Research to "Strong-Buy" Rating

Key Points

• Plus Therapeutics has been upgraded by Zacks Research from a "hold" rating to a "strong-buy" rating, indicating a positive outlook from analysts.
• Despite the upgrade, several analysts have recently dropped their price targets for the stock, with estimates ranging from $3.00 to $5.00, reflecting mixed sentiments among investment firms.
• Plus Therapeutics reported a quarterly earnings per share that beat consensus estimates, indicating momentum in financial performance amidst a challenging market.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report) was upgraded by investment analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports.

Several other equities research analysts have also weighed in on PSTV. Maxim Group dropped their price objective on shares of Plus Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Monday, August 18th. Wall Street Zen upgraded shares of Plus Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 16th. D. Boral Capital restated a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a research note on Thursday, September 25th. HC Wainwright dropped their price target on shares of Plus Therapeutics from $5.50 to $3.00 and set a "buy" rating on the stock in a research note on Friday, June 27th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Plus Therapeutics presently has an average rating of "Buy" and a consensus price target of $8.00.

Plus Therapeutics Stock Up 3.8%

PSTV opened at $0.70 on Monday. The firm has a market cap of $69.79 million, a price-to-earnings ratio of -0.31 and a beta of 0.81. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.31. The company's 50-day moving average price is $0.57 and its 200 day moving average price is $0.53.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.08. The business had revenue of $1.39 million for the quarter, compared to analyst estimates of $1.08 million. Research analysts anticipate that Plus Therapeutics will post -2.3 earnings per share for the current year.

Insiders Place Their Bets

In other Plus Therapeutics news, Director Robert P. Lenk bought 110,000 shares of Plus Therapeutics stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average cost of $0.49 per share, for a total transaction of $53,900.00. Following the completion of the acquisition, the director owned 139,327 shares of the company's stock, valued at approximately $68,270.23. This represents a 375.08% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.79% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Plus Therapeutics stock. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 117,454 shares of the company's stock, valued at approximately $41,000. Jane Street Group LLC owned approximately 0.19% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by institutional investors and hedge funds.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.